An injectable liquid crystal system for sustained delivery of entecavir
[Display omitted] Liquid crystal (LC) technology has attracted much interest for new injectable sustained-release (SR) formulations. In this study, an injectable liquid crystal-forming system (LCFS) including entecavir was prepared for the treatment of hepatitis B. In particular, an anchoring effect...
Gespeichert in:
| Veröffentlicht in: | International journal of pharmaceutics 2015-07, Vol.490 (1-2), p.265-272 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 272 |
|---|---|
| container_issue | 1-2 |
| container_start_page | 265 |
| container_title | International journal of pharmaceutics |
| container_volume | 490 |
| creator | Lim, Jong-Lae Ki, Min-Hyo Joo, Min Kyung An, Sung-Won Hwang, Kyu-Mok Park, Eun-Seok |
| description | [Display omitted]
Liquid crystal (LC) technology has attracted much interest for new injectable sustained-release (SR) formulations. In this study, an injectable liquid crystal-forming system (LCFS) including entecavir was prepared for the treatment of hepatitis B. In particular, an anchoring effect was introduced because LCFSs are relatively hydrophobic while entecavir is a slightly charged drug. The physicochemical properties of LCFSs were investigated by cryo-transmission electron microscopy (cryo-TEM), polarized optical microscopy, and small-angle X-ray scattering (SAXS), showing typical characteristics of the liquid crystalline phase, which was classified as the hexagonal phase. A pharmacokinetic study in rats showed sustained release of entecavir for 3–5 days with a basic LCFS formulation composed of sorbitan monooleate (SMO), phosphatidyl choline (PC), and tocopherol acetate (TA) as the main LC components. 1,2-Dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA), an anionic phospholipid, was added to increase the anchoring effect between the cationic entecavir and the anionic DPPA, which resulted in a 1.5-times increase in half-life in rats. In addition, anchoring was strengthened by optimizing the pH to 2.5–4.5, increasing the half-life in the rat and dog. Also, due to the increasing terminal half-life from rat to dog resulting from species differences, LCFS produced one week delivery of entecavir in rat and two weeks delivery in dog. Therefore, LCFS injection using the anchoring effect for entecavir can potentially be used to deliver the drug over more than 2 weeks or even 1 month for the treatment of hepatitis B. |
| doi_str_mv | 10.1016/j.ijpharm.2015.05.049 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1691595016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378517315004688</els_id><sourcerecordid>1691595016</sourcerecordid><originalsourceid>FETCH-LOGICAL-c365t-b2dcda01d13983ee8efdc14e5dc4c5f803f94c2c50d2c796dba04ae8b7be861e3</originalsourceid><addsrcrecordid>eNqFkM1LAzEQxYMotlb_BCVHL7tONpv9OEkpWoWCFz2HbDKLWfajTXYL_e9NafUqPHgwvDfD_Ai5ZxAzYNlTE9tm-61cFyfARAxBaXlB5qzIecTTPLskc-B5EQmW8xm58b4BgCxh_JrMkgwgBUjmZL3sqe0b1KOqWqSt3U3WUO0OflQt9cGwo_XgqJ_CxPZoqMHW7tEd6FBT7EfUam_dLbmqVevx7uwL8vX68rl6izYf6_fVchNpnokxqhKjjQJmGC8LjlhgbTRLURidalEXwOsy1YkWYBKdl5mpFKQKiyqvsMgY8gV5PO3dumE3oR9lZ73GtlU9DpOXLCuZKEUgFKLiFNVu8N5hLbfOdsodJAN5ZCgbeWYojwwlBKVl6D2cT0xVh-av9QstBJ5PAQyP7i066bXFXqOxLoCUZrD_nPgBTqCG0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1691595016</pqid></control><display><type>article</type><title>An injectable liquid crystal system for sustained delivery of entecavir</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Lim, Jong-Lae ; Ki, Min-Hyo ; Joo, Min Kyung ; An, Sung-Won ; Hwang, Kyu-Mok ; Park, Eun-Seok</creator><creatorcontrib>Lim, Jong-Lae ; Ki, Min-Hyo ; Joo, Min Kyung ; An, Sung-Won ; Hwang, Kyu-Mok ; Park, Eun-Seok</creatorcontrib><description>[Display omitted]
Liquid crystal (LC) technology has attracted much interest for new injectable sustained-release (SR) formulations. In this study, an injectable liquid crystal-forming system (LCFS) including entecavir was prepared for the treatment of hepatitis B. In particular, an anchoring effect was introduced because LCFSs are relatively hydrophobic while entecavir is a slightly charged drug. The physicochemical properties of LCFSs were investigated by cryo-transmission electron microscopy (cryo-TEM), polarized optical microscopy, and small-angle X-ray scattering (SAXS), showing typical characteristics of the liquid crystalline phase, which was classified as the hexagonal phase. A pharmacokinetic study in rats showed sustained release of entecavir for 3–5 days with a basic LCFS formulation composed of sorbitan monooleate (SMO), phosphatidyl choline (PC), and tocopherol acetate (TA) as the main LC components. 1,2-Dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA), an anionic phospholipid, was added to increase the anchoring effect between the cationic entecavir and the anionic DPPA, which resulted in a 1.5-times increase in half-life in rats. In addition, anchoring was strengthened by optimizing the pH to 2.5–4.5, increasing the half-life in the rat and dog. Also, due to the increasing terminal half-life from rat to dog resulting from species differences, LCFS produced one week delivery of entecavir in rat and two weeks delivery in dog. Therefore, LCFS injection using the anchoring effect for entecavir can potentially be used to deliver the drug over more than 2 weeks or even 1 month for the treatment of hepatitis B.</description><identifier>ISSN: 0378-5173</identifier><identifier>EISSN: 1873-3476</identifier><identifier>DOI: 10.1016/j.ijpharm.2015.05.049</identifier><identifier>PMID: 26004002</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>alpha-Tocopherol - chemistry ; Anchoring effect ; Animals ; Chemistry, Pharmaceutical ; Delayed-Action Preparations - administration & dosage ; Delayed-Action Preparations - chemistry ; Dogs ; Drug Delivery Systems - methods ; Entecavir ; Guanine - administration & dosage ; Guanine - analogs & derivatives ; Guanine - chemistry ; Half-Life ; Hexoses - chemistry ; Hydrophobic and Hydrophilic Interactions ; Injections - methods ; Liquid crystal ; Liquid Crystals - chemistry ; Male ; Pharmacokinetics ; Phenylpropionates - chemistry ; Phosphatidylcholines - chemistry ; Phospholipids - chemistry ; Rats ; Rats, Sprague-Dawley ; Scattering, Small Angle ; Sustained release injection ; X-Ray Diffraction - methods</subject><ispartof>International journal of pharmaceutics, 2015-07, Vol.490 (1-2), p.265-272</ispartof><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c365t-b2dcda01d13983ee8efdc14e5dc4c5f803f94c2c50d2c796dba04ae8b7be861e3</citedby><cites>FETCH-LOGICAL-c365t-b2dcda01d13983ee8efdc14e5dc4c5f803f94c2c50d2c796dba04ae8b7be861e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijpharm.2015.05.049$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26004002$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lim, Jong-Lae</creatorcontrib><creatorcontrib>Ki, Min-Hyo</creatorcontrib><creatorcontrib>Joo, Min Kyung</creatorcontrib><creatorcontrib>An, Sung-Won</creatorcontrib><creatorcontrib>Hwang, Kyu-Mok</creatorcontrib><creatorcontrib>Park, Eun-Seok</creatorcontrib><title>An injectable liquid crystal system for sustained delivery of entecavir</title><title>International journal of pharmaceutics</title><addtitle>Int J Pharm</addtitle><description>[Display omitted]
Liquid crystal (LC) technology has attracted much interest for new injectable sustained-release (SR) formulations. In this study, an injectable liquid crystal-forming system (LCFS) including entecavir was prepared for the treatment of hepatitis B. In particular, an anchoring effect was introduced because LCFSs are relatively hydrophobic while entecavir is a slightly charged drug. The physicochemical properties of LCFSs were investigated by cryo-transmission electron microscopy (cryo-TEM), polarized optical microscopy, and small-angle X-ray scattering (SAXS), showing typical characteristics of the liquid crystalline phase, which was classified as the hexagonal phase. A pharmacokinetic study in rats showed sustained release of entecavir for 3–5 days with a basic LCFS formulation composed of sorbitan monooleate (SMO), phosphatidyl choline (PC), and tocopherol acetate (TA) as the main LC components. 1,2-Dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA), an anionic phospholipid, was added to increase the anchoring effect between the cationic entecavir and the anionic DPPA, which resulted in a 1.5-times increase in half-life in rats. In addition, anchoring was strengthened by optimizing the pH to 2.5–4.5, increasing the half-life in the rat and dog. Also, due to the increasing terminal half-life from rat to dog resulting from species differences, LCFS produced one week delivery of entecavir in rat and two weeks delivery in dog. Therefore, LCFS injection using the anchoring effect for entecavir can potentially be used to deliver the drug over more than 2 weeks or even 1 month for the treatment of hepatitis B.</description><subject>alpha-Tocopherol - chemistry</subject><subject>Anchoring effect</subject><subject>Animals</subject><subject>Chemistry, Pharmaceutical</subject><subject>Delayed-Action Preparations - administration & dosage</subject><subject>Delayed-Action Preparations - chemistry</subject><subject>Dogs</subject><subject>Drug Delivery Systems - methods</subject><subject>Entecavir</subject><subject>Guanine - administration & dosage</subject><subject>Guanine - analogs & derivatives</subject><subject>Guanine - chemistry</subject><subject>Half-Life</subject><subject>Hexoses - chemistry</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>Injections - methods</subject><subject>Liquid crystal</subject><subject>Liquid Crystals - chemistry</subject><subject>Male</subject><subject>Pharmacokinetics</subject><subject>Phenylpropionates - chemistry</subject><subject>Phosphatidylcholines - chemistry</subject><subject>Phospholipids - chemistry</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Scattering, Small Angle</subject><subject>Sustained release injection</subject><subject>X-Ray Diffraction - methods</subject><issn>0378-5173</issn><issn>1873-3476</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkM1LAzEQxYMotlb_BCVHL7tONpv9OEkpWoWCFz2HbDKLWfajTXYL_e9NafUqPHgwvDfD_Ai5ZxAzYNlTE9tm-61cFyfARAxBaXlB5qzIecTTPLskc-B5EQmW8xm58b4BgCxh_JrMkgwgBUjmZL3sqe0b1KOqWqSt3U3WUO0OflQt9cGwo_XgqJ_CxPZoqMHW7tEd6FBT7EfUam_dLbmqVevx7uwL8vX68rl6izYf6_fVchNpnokxqhKjjQJmGC8LjlhgbTRLURidalEXwOsy1YkWYBKdl5mpFKQKiyqvsMgY8gV5PO3dumE3oR9lZ73GtlU9DpOXLCuZKEUgFKLiFNVu8N5hLbfOdsodJAN5ZCgbeWYojwwlBKVl6D2cT0xVh-av9QstBJ5PAQyP7i066bXFXqOxLoCUZrD_nPgBTqCG0w</recordid><startdate>20150725</startdate><enddate>20150725</enddate><creator>Lim, Jong-Lae</creator><creator>Ki, Min-Hyo</creator><creator>Joo, Min Kyung</creator><creator>An, Sung-Won</creator><creator>Hwang, Kyu-Mok</creator><creator>Park, Eun-Seok</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150725</creationdate><title>An injectable liquid crystal system for sustained delivery of entecavir</title><author>Lim, Jong-Lae ; Ki, Min-Hyo ; Joo, Min Kyung ; An, Sung-Won ; Hwang, Kyu-Mok ; Park, Eun-Seok</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c365t-b2dcda01d13983ee8efdc14e5dc4c5f803f94c2c50d2c796dba04ae8b7be861e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>alpha-Tocopherol - chemistry</topic><topic>Anchoring effect</topic><topic>Animals</topic><topic>Chemistry, Pharmaceutical</topic><topic>Delayed-Action Preparations - administration & dosage</topic><topic>Delayed-Action Preparations - chemistry</topic><topic>Dogs</topic><topic>Drug Delivery Systems - methods</topic><topic>Entecavir</topic><topic>Guanine - administration & dosage</topic><topic>Guanine - analogs & derivatives</topic><topic>Guanine - chemistry</topic><topic>Half-Life</topic><topic>Hexoses - chemistry</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>Injections - methods</topic><topic>Liquid crystal</topic><topic>Liquid Crystals - chemistry</topic><topic>Male</topic><topic>Pharmacokinetics</topic><topic>Phenylpropionates - chemistry</topic><topic>Phosphatidylcholines - chemistry</topic><topic>Phospholipids - chemistry</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Scattering, Small Angle</topic><topic>Sustained release injection</topic><topic>X-Ray Diffraction - methods</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lim, Jong-Lae</creatorcontrib><creatorcontrib>Ki, Min-Hyo</creatorcontrib><creatorcontrib>Joo, Min Kyung</creatorcontrib><creatorcontrib>An, Sung-Won</creatorcontrib><creatorcontrib>Hwang, Kyu-Mok</creatorcontrib><creatorcontrib>Park, Eun-Seok</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of pharmaceutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lim, Jong-Lae</au><au>Ki, Min-Hyo</au><au>Joo, Min Kyung</au><au>An, Sung-Won</au><au>Hwang, Kyu-Mok</au><au>Park, Eun-Seok</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An injectable liquid crystal system for sustained delivery of entecavir</atitle><jtitle>International journal of pharmaceutics</jtitle><addtitle>Int J Pharm</addtitle><date>2015-07-25</date><risdate>2015</risdate><volume>490</volume><issue>1-2</issue><spage>265</spage><epage>272</epage><pages>265-272</pages><issn>0378-5173</issn><eissn>1873-3476</eissn><abstract>[Display omitted]
Liquid crystal (LC) technology has attracted much interest for new injectable sustained-release (SR) formulations. In this study, an injectable liquid crystal-forming system (LCFS) including entecavir was prepared for the treatment of hepatitis B. In particular, an anchoring effect was introduced because LCFSs are relatively hydrophobic while entecavir is a slightly charged drug. The physicochemical properties of LCFSs were investigated by cryo-transmission electron microscopy (cryo-TEM), polarized optical microscopy, and small-angle X-ray scattering (SAXS), showing typical characteristics of the liquid crystalline phase, which was classified as the hexagonal phase. A pharmacokinetic study in rats showed sustained release of entecavir for 3–5 days with a basic LCFS formulation composed of sorbitan monooleate (SMO), phosphatidyl choline (PC), and tocopherol acetate (TA) as the main LC components. 1,2-Dipalmitoyl-sn-glycero-3-phosphatidic acid (DPPA), an anionic phospholipid, was added to increase the anchoring effect between the cationic entecavir and the anionic DPPA, which resulted in a 1.5-times increase in half-life in rats. In addition, anchoring was strengthened by optimizing the pH to 2.5–4.5, increasing the half-life in the rat and dog. Also, due to the increasing terminal half-life from rat to dog resulting from species differences, LCFS produced one week delivery of entecavir in rat and two weeks delivery in dog. Therefore, LCFS injection using the anchoring effect for entecavir can potentially be used to deliver the drug over more than 2 weeks or even 1 month for the treatment of hepatitis B.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26004002</pmid><doi>10.1016/j.ijpharm.2015.05.049</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0378-5173 |
| ispartof | International journal of pharmaceutics, 2015-07, Vol.490 (1-2), p.265-272 |
| issn | 0378-5173 1873-3476 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1691595016 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | alpha-Tocopherol - chemistry Anchoring effect Animals Chemistry, Pharmaceutical Delayed-Action Preparations - administration & dosage Delayed-Action Preparations - chemistry Dogs Drug Delivery Systems - methods Entecavir Guanine - administration & dosage Guanine - analogs & derivatives Guanine - chemistry Half-Life Hexoses - chemistry Hydrophobic and Hydrophilic Interactions Injections - methods Liquid crystal Liquid Crystals - chemistry Male Pharmacokinetics Phenylpropionates - chemistry Phosphatidylcholines - chemistry Phospholipids - chemistry Rats Rats, Sprague-Dawley Scattering, Small Angle Sustained release injection X-Ray Diffraction - methods |
| title | An injectable liquid crystal system for sustained delivery of entecavir |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T12%3A51%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20injectable%20liquid%20crystal%20system%20for%20sustained%20delivery%20of%20entecavir&rft.jtitle=International%20journal%20of%20pharmaceutics&rft.au=Lim,%20Jong-Lae&rft.date=2015-07-25&rft.volume=490&rft.issue=1-2&rft.spage=265&rft.epage=272&rft.pages=265-272&rft.issn=0378-5173&rft.eissn=1873-3476&rft_id=info:doi/10.1016/j.ijpharm.2015.05.049&rft_dat=%3Cproquest_cross%3E1691595016%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1691595016&rft_id=info:pmid/26004002&rft_els_id=S0378517315004688&rfr_iscdi=true |